3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit

3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit is organized by Hanson Wade and will be held from Mar 02 - 04, 2021.

The 3rd Chronic Kidney Disease Drug Development (CKD3) Summit is the industry’s definitive forum dedicated to developing more innovative, targeted, and clinically successful drugs to more meaningfully address chronic kidney disease is back!

Gathering cross-industry experts from nephrology, cardiology, and endocrinology to analyze and overcome challenges in the diabetic kidney and rare glomerular disease drug development, CKD3 is the must-attend forum for focused discussion and actionable insights to further CKD drug development.

From foundational science for target identification through to patient recruitment and costings of approved drugs in orphan indications, hear from over 30 speakers and gain candid insights on the latest results to inform your pipeline from concept to clinical trials.

What You Will Gain from Attending CKD3
1..Networking: Network one-to-one with cross-industry, cross-discipline experts prioritizing DKD, FSGS, IgA nephropathy, C3 glomerulopathy, lupus nephritis, Alport’s syndrome and polycystic kidney disease to understand their work to accelerate drugs to dramatically impact patient lives
2. Actionable Insights: Hear first-hand how the latest scientific understanding is being applied to pipeline progress enabling you to benchmark your decisions against others in the field and gain innovative foresight to address challenges before you reach them.
3. Sharing your data: Present your own work to your peers and thought leaders to gain critical and candid feedback that could be pivotal to opening up partnerships and changing the trajectory of your program

From navigating trial endpoints to the potential and practicalities of precision medicine, CKD3 will unite preclinical, clinical, and medical affairs decision-makers under one roof for the third year.
•  Interrogate patient data sets to identify genetic drivers and targetable mutations to advance the progress of more precise, targeted, and disease-modifying precision medicine
•  Understand mechanisms driving beneficial effects of SGLT-2 inhibition and define the standard of care in high eGFR populations to inform additional drug development opportunity and strategy
•  Assess novel bioengineering technologies to enhance disease recapitulation in vivo and improve the predictability of drug discovery for glomerular diseases
•  Leverage the potential of AI to create and manipulate hypothesis from large data sets for a greater understanding of mechanisms driving disease and meaningful targets for drug development
•  Navigate patient recruitment, regulatory approval, and reimbursement for orphan indications, and assess the opportunity to deliver a wider public health benefit at a later stage.